SPOTLIGHT: ImClone pushes new indication


Following the successful conclusion of trials into Erbitux for head and neck cancer, ImClone says it will seek expanded use of the cancer drug in the third quarter. Erbitux is currently indicated for colorectal cancer. Story

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.